Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2020

Liu Yang, Pang Ying, Zhu Boqun, Uher Ondrej, Caisova Veronika, Huynh Thanh-Truc, Taieb David, Hadrava Vanova Katerina, Ghayee Hans Kumar, Neuzil Jiri, Levine Mark, Yang Chunzhang, Pacak Karel

Abstract excerpt

PURPOSE: Pheochromocytomas and paragangliomas (PCPG) are usually benign neuroendocrine tumors. However, PCPGs with mutations in the succinate dehydrogenase B subunit (SDHB) have a poor prognosis and frequently develop metastatic lesions. SDHB-mutated PCPGs exhibit dysregulation in oxygen metabolic pathways, including pseudohypoxia and formation of reactive oxygen species, suggesting that targeting the redox...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antioxidants
Share to Ascorbic Acid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Gene Knockdown Techniques

Share to Paraganglioma

Share to Pheochromocytoma

Share to Succinate Dehydrogenase

Source

Open in PubMed Open full text

Identifiers

PMID: 32152203
DOI: 10.1158/1078-0432.CCR-19-2335
PMCID: PMC7443979

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid.PMID 32152203Read ↗

Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate.Semantic proximity Read ↗

Epigenetic and metabolic reprogramming of SDH-deficient paragangliomasSemantic proximity Read ↗

Pro-tumoural effects of vitamin C supplementation in a zebrafish model for SDHB-associated PPGL.Semantic proximity Read ↗

The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.Semantic proximity Read ↗

Loss of SDHB Elevates Catecholamine Synthesis and Secretion Depending on ROS Production and HIF Stabilization.Semantic proximity Read ↗

MITOCHONDRIA: Succinate dehydrogenase subunit B-associated phaeochromocytoma and paraganglioma.Semantic proximity Read ↗

Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.Semantic proximity Read ↗

A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− ratsSemantic proximity Read ↗

Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings.Semantic proximity Read ↗

Hypothesis: Why Different Types of SDH Gene Variants Cause Divergent Tumor Phenotypes.Semantic proximity Read ↗

Clinical implications of the oncometabolite succinate in SDHx ‐mutation carriersSemantic proximity Read ↗

The Emerging Role of Succinate Dehyrogenase Genes (SDHx) in TumorigenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.